FDA DEVICE FACTS
ArteraAI Breast
Artera, Inc.
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
ArteraAI Breast is a software only device intended to analyze scanned histopathology whole slide image (WSI) from treatment-naïve breast resection specimens prepared from formalin fixed paraffin-embedded (FFPE) tissue and stained using Hematoxylin & Eosin (H&E) stains. Additional inputs to ArteraAI Breast include the following physician-provided clinical variables:
- Age
- Tumor size
- Nodal status ArteraAI Breast provides 5- and 10-year risks of distant metastasis and ArteraAI risk score for adult patients with HR+/HER2-, N0 or N1, early-stage invasive breast cancer without clinically or pathologically defined metastases after surgical tumor resection and who are candidates for standard of care adjuvant therapy. ArteraAI Breast is intended to assist physicians with prognostic risk-based decisions along with other clinicopathological factors. ArteraAI Breast is intended to utilize WSIs acquired from FDA-cleared interoperable scanners and file formats that have been validated for use with this device.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。